SCHEMBL15575892

SCHEMBL15575892

Brc1ccn(-c2ccc[nH]2)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663207 0.76 AURKA (0.33)
SCHEMBL1038873 0.76
SCHEMBL3152148 0.69 LMNA (0.35)
SCHEMBL28947028 0.66 COMT (0.48)
SCHEMBL7189439 0.58 HDAC8 (0.34)
SCHEMBL1037428 0.57 ALDH1A1 (0.31)
SCHEMBL10370901 0.57 AURKA (0.34)
SCHEMBL7195400 0.57 DAO (0.34)
SCHEMBL1581968 0.57 NOTUM (0.42)
SCHEMBL9217273 0.57 DAO (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2892904-B1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS CB THERAPEUTICS INC (KY) 2018-10-17 EP disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 US disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 US disclosed
EP-2892904-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS Crown Bioscience Inc. (Taiwan) (CN) 2015-07-15 EP disclosed
WO-2014032498-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS CROWN BIOSCIENCE INC. (TAICANG) (CN) 2014-03-06 WO disclosed